Clinical Trials Logo

Filter by:
NCT ID: NCT06149533 Not yet recruiting - Cancer Clinical Trials

Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients

Thrombosis
Start date: November 30, 2023
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of edoxaban in the prevention of tumor catheter-related thrombosis (CVC/PICC) in high-risk patients

NCT ID: NCT06149377 Completed - Breast Cancer Clinical Trials

Impact of a Predictive Model on Sentinel Lymph Node Biopsy in Initially Lymph Node-positive, HER2-positive Breast Cancer

Start date: April 1, 2012
Phase:
Study type: Observational

The aim of the study was to develop and validate a nomogram to assess axillary pathological complete response (pCR) in patients with initially lymph node-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer and test its performance in guiding patient selection for sentinel lymph node biopsy (SLNB) following neoadjuvant systemic therapy (NST).

NCT ID: NCT06149260 Recruiting - Fibrosis Clinical Trials

Subcutaneous Semaglutide in Systemic Scleroderma

Start date: February 29, 2024
Phase: Phase 1
Study type: Interventional

This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis

NCT ID: NCT06149195 Enrolling by invitation - Clinical trials for Rest Gated Myocardial Perfusion Imaging in Heart Failure

18F-MFBG Cardiac Imaging for Heart Failure Administration

Start date: January 1, 2024
Phase:
Study type: Observational

The clinical feasibility of 18F-FMBG cardiac PET imaging will be observed in sympathetic nervous system activity in patients with heart failure, predicted cardiac events, guided ICD implantation, and evaluated therapy efficiency.

NCT ID: NCT06149169 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Start date: August 17, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.

NCT ID: NCT06149130 Recruiting - Breast Cancer Clinical Trials

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

Start date: January 11, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, multicenter Phase II study of patients with advanced HR+/HER2- breast cancer who are untreated or have failed previous first-line endocrine therapy怂The primary objective of this study was to explore the efficacy and safety of the PD-L1 inhibitor adebrelimab in combination with the CDK4/6 inhibitor Dalpiciclib and standard endocrine therapy in advanced HR+/ HER2-breast cancer.

NCT ID: NCT06149117 Completed - Clinical trials for Upper Respiratory Tract Infection

Bioequivalence Study of Azithromycin Capsule and Reference Formulation Sumamed * in Healthy Adult Subjects in China

Start date: November 16, 2022
Phase: Phase 4
Study type: Interventional

Main research purpose To investigate the pharmacokinetics of the test preparation azithromycin capsule and the reference preparation azithromycin capsule (Sumamed®) in Chinese healthy adult subjects by single oral administration in fasting state, and to evaluate the bioequivalence of the two preparations by oral administration in fasting state. Secondary research purpose To investigate the safety of the test preparation azithromycin capsule and the reference preparation "Sumamed®" in healthy subjects.

NCT ID: NCT06149091 Recruiting - Clinical trials for Iatrogenic Endobronchial Bleeding

Control of Iatrogenic Endobronchial Bleeding by Tranexamic Acid, Adrenalin and Hemagglutinase

Start date: December 1, 2023
Phase: Early Phase 1
Study type: Interventional

A prospective national multi-center study will be conducted to evaluate the effectiveness of hemocoagulase in iatrogenic airway bleeding in a large class III hospital, such as the Second Affiliated Hospital of Harbin Medical University, the First Affiliated Hospital of Nanchang University, and to compare it with topical epinephrine and tranexamic acid in a prospective double-blind cluster randomized controlled trial.

NCT ID: NCT06149039 Recruiting - Dermatomyositis Clinical Trials

Study on Lymphocyte Subsets of Peripheral Blood in Patients With Nonmyopathic Dermatomyositis Complicated With Pulmonary Interstitial Disease

Start date: April 1, 2023
Phase:
Study type: Observational

To detect the changes of lymphocyte subsets in peripheral blood of non-myopathic dermatomyositis with pulmonary interstitial disease, classical dermatomyositis with pulmonary interstitial disease, rheumatism with non-inflammatory myopathy with pulmonary interstitial disease and healthy adults among the 4 groups, and to detect the related cytokines secreted by lymphocyte subsets Th1,Th2 and Th17. Clinical features, distribution of peripheral lymphocyte subsets ratio and related cytokine content secreted by each lymphocyte subset were analyzed in each group, so as to explore the pathogenesis characteristics of nonmyopathic dermatomyositis complicated with pulmonary interstitial disease, in order to facilitate clinical guidance for diagnosis and treatment.

NCT ID: NCT06148857 Not yet recruiting - Cataract Clinical Trials

Total Corneal Astigmatism Prevalence in Cataract Patients

Start date: November 2023
Phase:
Study type: Observational

The purpose of this study is to report the prevalence data for total corneal astigmatism (TCA) in cataract surgery candidates.